AURORA SPINE CORP.

Aurora Spine reported Q1 2026 revenue of $4.44 million (+0.4% year‑on‑year) with a significantly improved gross profit margin of 62.6% (up 460 basis points). Net loss narrowed 42% to $203,000, and EBITDAC was positive at $107,000. The stock fell 2.04% to $0.245 after the results. The company plans to expand its sales team by 50% and expects growth from the launch of SiLO-X in the second half of the year. » Więcej na de.investing.com

Aurora Spine posted record revenue of $5.02 million in Q4 2025, up 14% sequentially and 6.8% year-over-year. Gross profit margin improved to 62.4% and net loss narrowed to $41,000 from $653,000 in the year-ago quarter. ZIP and SiLO contributed 60% of revenue; EBITDAC rose to $301,000. For 2026, management expects growth from DEXA technology, notably the DEXA-L implant, and plans to expand the sales team by 50%. » Więcej na de.investing.com

Aurora Spine recorded a 7.1% revenue decline in the third quarter of 2025 to USD 4.43 million, with a net loss of USD 842,000 and cash on hand of just under USD 700,000. Gross margin improved slightly to 60.9% and operating expenses fell to USD 2.81 million. The company launched the facet pain implant Hydra ARO and the anterior lumbar fusion system DEXA L, is targeting monthly revenue above USD 1.4 million, and plans to expand the DEXA L kits in 2026. The stock fell 6.67% after the results were released. » Więcej na de.investing.com

Aurora Spine Corporation increased revenue in the second quarter of 2025 by 10.2% to $4.5 million, with an improved gross margin of 62.2%, but still posted a net loss of $199,000. The company is introducing new products such as Hydra Arrow and DEXA L, plans to expand its sales team, and expects further growth in H2 2025 driven by rising demand for minimally invasive spinal procedures. Management expressed optimism for the second half of the year but flagged risks from competition and macroeconomic uncertainty. » Więcej na de.investing.com